Norjizak Injection: A Critical Risk for Transmitting Blood-Borne Infectious Diseases

authors:

avatar Zahra Alam Mehrjerdi 1 , *

Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, IR Iran

how to cite: Alam Mehrjerdi Z. Norjizak Injection: A Critical Risk for Transmitting Blood-Borne Infectious Diseases. Hepat Mon. 2013;13(4):e8272. https://doi.org/10.5812/hepatmon.8272.

References

  • 1.

    Ramezani A, Mohraz M, Gachkar L. Epidemiologic situation of human immunodeficiency virus (HIV/AIDS patients) at a private clinic in Tehran, Iran. Arch Iran Med. 2006;9(4):315-8. [PubMed ID: 17061601].

  • 2.

    Sharif M, Sherif A, Sayyah M. Frequency of HBV, HCV and HIV infections among hospitalized injecting drug users in Kashan. Indian J Sex Transm Dis. 2009;30(1):28-30. [PubMed ID: 21938111]. https://doi.org/10.4103/0253-7184.55477.

  • 3.

    Hassannejad R, Kassaian N, Ataei B, Adibi P. High risky behaviors among intravenous drug users in Isfahan, Iran: A study for hepatitis C harm reduction programs. Int J Prev Med. 2012;3(Suppl 1):S73-8. [PubMed ID: 22826773].

  • 4.

    Razzaghi EM, Movaghar AR, Green TC, Khoshnood K. Profiles of risk: a qualitative study of injecting drug users in Tehran, Iran. Harm Reduct J. 2006;3:12. [PubMed ID: 16545137]. https://doi.org/10.1186/1477-7517-3-12.

  • 5.

    Mir-Nasseri MM, Mohammadkhani A, Tavakkoli H, Ansari E, Poustchi H. Incarceration is a major risk factor for blood-borne infection among intravenous drug users: Incarceration and blood borne infection among intravenous drug users. Hepat Mon. 2011;11(1):19-22. [PubMed ID: 22087111].

  • 6.

    Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy. 2007;18(5):359-63. [PubMed ID: 17854723]. https://doi.org/10.1016/j.drugpo.2007.02.007.

  • 7.

    Amin-Esmaeili M, Rahimi-Movaghar A, Razaghi EM, Baghestani AR, Jafari S. Factors correlated with hepatitis c and b virus infections among injecting drug users in Tehran, IR Iran. Hepat Mon. 2012;12(1):23-31. [PubMed ID: 22451840]. https://doi.org/10.5812/kowsar.1735143X.806.

  • 8.

    Alavi SM, Behdad F. Seroprevalence study of hepatitis C and Hepatitis B virus among hospitalized intravenous drug users in Ahvaz, Iran (2002-2006). Hepat Mon. 2010;10(2):101-4. [PubMed ID: 22312381].

  • 9.

    Zamani S, Ono-Kihara M, Ichikawa S, Kihara M. Potential for sexual transmission of HIV infection from male injecting-drug users who have sex with men in Tehran, Iran. Sex Transm Dis. 2010;37(11):715-8. [PubMed ID: 20693938]. https://doi.org/10.1097/OLQ.0b013e3181e2c73f.

  • 10.

    Siavash M, Janghorbani M, Gheshlaghi F, Adeli SH, Saljoughi M, Moradi F, et al. A case series of abuse of a new opioid combination, Norjizak. J Addict Dis. 2009;28(2):180-5. [PubMed ID: 19340681]. https://doi.org/10.1080/10550880902772928.

  • 11.

    Nemati A. Kerman, Iran: Kerman University of Medical Sciences; 2007. Assessment and follow up of avascular necrosis of femoral head following tamjizak and norjizak in drug abusers [dissertation].

  • 12.

    Shekarchizadeh H, Ekhtiari H, Khami MR, Virtanen JI. Patterns of pre-treatment drug abuse, drug treatment history and characteristics of addicts in methadone maintenance treatment in Iran. Harm Reduct J. 2012;9(1):18. [PubMed ID: 22676557]. https://doi.org/10.1186/1477-7517-9-18.

  • 13.

    Shokuhi S, Nikfarjam Shirazi E, Ali Asgari A, Gachkar L. Prevalence of anergy among hospitalized drug users in southern Tehran. Iran J Clin Infect Dis. 2008;3(1):29-33.

  • 14.

    Koushesh HR, Afshari R. A new illicit opioid dependence outbreak, evidence for a combination of opioids and steroids. Drug Chem Toxicol. 2009;32(2):114-9. [PubMed ID: 19514947]. https://doi.org/10.1080/01480540802588485.

  • 15.

    Khorvash F, Fasihi Dastjerdi M, Zarefar S, Jonaidi Jafari N. Infectious complications and mortality due to Norgesic in comparison with other injecting narcotics. Militar Med J. 2006;8(2):149-54.

  • 16.

    Tayeri K, Radfar SR, Yaran M, Kassaian N, Nokhodian Z, Ataei B, et al. Isolation of hepatitis C virus in norjizac vials. Hepat Mon. 2010;10(1):65-6. [PubMed ID: 22308130].

  • 17.

    Farnia M, Ebrahimi B, Shams A, Zamani S. Scaling up methadone maintenance treatment for opioid-dependent prisoners in Iran. Int J Drug Policy. 2010;21(5):422-4. [PubMed ID: 20413287]. https://doi.org/10.1016/j.drugpo.2010.03.008.

  • 18.

    Razzaghi E, Nassirimanesh B, Afshar P, Ohiri K, Claeson M, Power R. HIV/AIDS harm reduction in Iran. Lancet. 2006;368(9534):434-5. [PubMed ID: 16890814]. https://doi.org/10.1016/S0140-6736(06)69132-0.

  • 19.

    Noori R, Narenjiha H, Aghabakhshi H, Habibi G, Khoshkrood Mansoori B. Methadone maintenance therapy outcomes in Iran. Subst Use Misuse. 2012;47(7):767-73. [PubMed ID: 22416897]. https://doi.org/10.3109/10826084.2010.517726.

  • 20.

    Vazirian M, Nassirimanesh B, Zamani S, Ono-Kihara M, Kihara M, Ravari SM, et al. Needle and syringe sharing practices of injecting drug users participating in an outreach HIV prevention program in Tehran, Iran: a cross-sectional study. Harm Reduct J. 2005;2:19. [PubMed ID: 16212655]. https://doi.org/10.1186/1477-7517-2-19.

  • 21.

    Zamani S, Vazirian M, Nassirimanesh B, Razzaghi EM, Ono-Kihara M, Mortazavi Ravari S, et al. Needle and syringe sharing practices among injecting drug users in Tehran: a comparison of two neighborhoods, one with and one without a needle and syringe program. AIDS Behav. 2010;14(4):885-90. [PubMed ID: 18483849]. https://doi.org/10.1007/s10461-008-9404-2.